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Let’s make Golgi
 
Does the Golgi self-organize or
does it form around an instructive
 
template? Evidence on both sides is
piling up, but a deﬁnitive conclusion
is proving elusive.
 
In the battle to define the Golgi, 
 
discussions easily spiral into what can 
appear like nitpicking. In a contentious 
poster session, an entire worldview 
rests on whether you think a particular 
mutant is arrested with vesicles that are 
 
close to but distinct from the ER or 
almost budded from but still attached 
to the ER.
Sometimes obscured by these details 
are the larger issues. This debate “gets 
to the fundamental issue of how you 
 
think of the Golgi,” says Ben Glick of 
the University of Chicago (Chicago, IL). 
“The dogma has been that you need a 
template to build an organelle. But in 
the secretory system it’s possible in 
principle that you could get de novo 
 
organization of structure. That’s the 
issue that stirs people emotionally and 
intellectually.”
Then there are the collateral issues. 
 
There is an ongoing controversy about 
the nature of forward transport through 
the Golgi—it may occur via forward 
movement of small vesicles, or by 
gradual maturation of one cisterna 
to form the next. The cisternal 
maturation model “argues for a Golgi 
that can be made and consumed,” says 
Graham Warren (Yale University, 
 
New Haven, CT)—a situation that is 
more difficult to reconcile with Warren’s 
template-determined universe.
 
Even more confusing is the situation 
in mitosis. Accounts vary wildly on 
how much of the Golgi disappears into 
the ER during mitosis. The answer 
would determine to what extent the cell 
has to rebuild the Golgi after mitosis, 
and what method it might use to do so.
Several laboratories have made 
 
major contributions to address these 
 
issues. But none define them so clearly as 
those of Warren and Jennifer Lippincott-
Schwartz (National Institutes of Health, 
Bethesda, MD). At almost every turn, 
on almost every issue, it seems that 
Warren and Lippincott-Schwartz reach 
opposite conclusions, sometimes based 
on similar or identical data.
And yet, at least in public, there is a 
remarkable lack of rancor. “These are 
not easy experiments for us to do,” says 
Warren. “It’s all cutting-edge research 
and we are pushing the technology to 
the limit. Part of that is that you push 
your own interpretation.” For her part, 
Lippincott-Schwartz approaches a 
lengthy poster-session debate with 
Warren with something approaching 
glee. This is not triumphal glee, 
however. Rather, Lippincott-Schwartz 
seems to relish the opportunity to 
exchange ideas, and on this point 
Warren agrees. “Complacency is the 
worst thing to have in a field,” he says. 
The debate “has made all of us think a 
lot harder.”
 
A drug and two reversals
 
Brefeldin A (BFA) is a remarkable 
 
compound. This fungal metabolite is 
not only specific, it also has a dramatic 
effect on a cell biological problem that 
is otherwise difficult to tackle. By 
inhibiting an exchange factor for the 
small GTPase Arf, BFA makes Arf fall 
off Golgi membranes, thus triggering 
the absorption of Golgi contents 
back into the ER. The ability of the 
Golgi to recover from this treatment 
was the first evidence that it may be 
possible to rebuild the Golgi from 
dispersed (or more accurately, ER-
localized) components.
But then Warren countered with 
his discovery and characterization of 
several Golgi matrix proteins. These 
proteins, such as Grasp65 and GM130, 
were left behind after either Triton 
extraction of the Golgi, or BFA treat-
ment. This led Warren to dub them 
“matrix” proteins, and to suggest that 
they form a scaffold for reforming 
the Golgi. He saw a similar pattern 
when he blocked exit from the ER 
using a mutant in another GTPase, 
Sar1—Golgi enzymes were stuck in the 
ER but the matrix proteins remained 
in a distinct, Golgi-like distribution.
Two papers in this issue contest the 
matrix interpretation. Brian Storrie 
(Virginia Tech, Blacksburg, VA) uses 
a higher concentration of the Sar1 
mutant used by Warren (which is stuck 
in the active, GTP-loaded state) and 
finds that now both Golgi enzymes and 
matrix proteins leave the Golgi (see 
Miles et al. on page 543 and Fig. 1). 
Lippincott-Schwartz uses an alternative 
Sar1 mutant, this one stuck in the 
 
inactive, GDP-loaded state, to show 
that Golgi enzymes and matrix proteins 
can be forced back into the ER (see 
Ward et al. on page 557 and Fig. 2).
In FRAP experiments, Ward et al. 
also show that Golgi matrix proteins 
can exchange dynamically rather 
than acting as a static matrix.
 
Dynamic interpretations
 
These experiments may disprove the 
extreme version of a static matrix. But 
they are consistent with a dynamic 
matrix (at least part of which is always 
present in the Golgi region), and they 
 
In the Golgi conflict, 
 
interpretation is all.
Figure 1. It takes a higher concentration of 
dominant Sar1 (in the GTP form) to force a 
matrix protein out of the Golgi region. 
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stop a long way short of proving the 
counter-proposal of a Golgi that can 
be rebuilt after dispersal. “The only 
thing that has been shown is that a 
lot of Golgi proteins are subject to 
recycling,” says Tommy Nilsson 
(European Molecular Biology 
Laboratory, Heidelberg, Germany). 
What is needed, he says, is an experiment 
in which proteins are forced into and 
then released from the ER using a 
temperature-sensitive Sar1 mutant. 
“Then you can address whether the 
Golgi is a self-forming organelle or if 
it needs a template.”
So far it has not been possible to 
make a temperature-sensitive Sar1. 
But that hasn’t stopped the participants 
from coming up with other, less 
direct tests of their models. Perhaps 
most direct has been Warren’s 
creation of cytoplasts. These cell 
fragments lack a nucleus and Golgi, 
but retain a dispersed ER. In support 
of Warren’s proposed template 
requirement, the cytoplasts cannot 
form a new Golgi. Lippincott-Schwartz 
believes that the cytoplast ER may lack 
one or more components (such as Arf) 
that are sequestered in the Golgi. 
Microinjection experiments to 
resolve this issue are extremely 
difficult and as yet have not yielded 
any different results, according to 
Warren.
The cytoplasts do, however, form 
a new Golgi if the original cells are 
pretreated with BFA. Warren believes 
that fragments of Golgi matrix can 
now disperse and enter the cytoplast, 
thus providing centers for Golgi 
reformation.
But, in her paper in this issue, 
Lippincott-Schwartz claims that the 
matrix-containing clusters seen with 
BFA or active Sar1 are not Golgi 
remnants. Based on exchange data 
and the presence of the CopII coat 
protein Sec13, she says that they are 
ER exit sites produced from the ER. 
“Once you get the result with BFA 
[in cytoplasts], that means the Golgi 
can form de novo,” she says, “because 
the peripheral structures are not 
Golgi-derived.”
 
Template or enzyme?
 
As the debate narrows to a discussion 
of specialized ER exit sites versus 
specialized Golgi fragments, what really 
differentiates the two viewpoints? 
“Whether the system can be built from 
scratch from the ER is the bottom line,” 
says Lippincott-Schwartz. “Graham 
thinks there is some kind of stable 
element that is serving as a scaffold, and 
that has no enzymatic function. My 
view is that this can be done by self-
organizing principles via an enzymatic 
process.”
And Lippincott-Schwartz has her 
own idea of what that enzymatic process 
might be. “What maintains the system 
is the activity of the Sar/CopII and 
Arf/CopI systems,” she says. “Sar sorts 
proteins out of the ER, partitions them 
into a subdomain. Arf allows the 
subdomain to completely differentiate 
from the ER into the Golgi. It’s a two-
step process to building a Golgi.”
Lippincott-Schwartz says that the 
template is only needed under the 
original model of vesicle-based Golgi 
transport, in which there must be a 
defined acceptor compartment to greet 
the vesicle upon arrival. But homotypic 
fusion of ER-derived vesicles, followed by 
coat-mediated sorting of some 
proteins back to the ER, might achieve 
the same goal.
Of course, what is possible in theory 
is not always what occurs in practice. 
Warren suspects that eventually a Golgi 
may be able to form without a template, 
but this would not occur on a relevant 
time scale. “These are very complex 
organelles,” he says. “If you took all 
these components you must be looking 
at a few hundred or thousand proteins. 
That could take an enormous time to 
self-assemble. The difference between 
us is kinetic.” As an example of this 
kinetic argument Warren cites centrioles, 
which under certain circumstances can 
form de novo but whose formation is 
usually greatly accelerated by the 
seeding of an existing centriole.
The time scale of most relevance to 
the process of Golgi dynamics covers the 
period during and following mitosis. 
Lippincott-Schwartz believes that the 
 
Golgi is completely absorbed into the 
ER during mitosis because of an 
inhibition of the Sar1 and Arf systems. 
Warren feels many of these results 
were compromised by GFP fusion 
proteins that were retained in the ER 
because of misfolding, although 
Lippincott-Schwartz points out that her 
group has seen the same redistribution 
of endogenous proteins using antibody 
staining. According to Vivek Malhotra 
(University of California, San Diego, 
CA), “we don’t know where the Golgi 
membranes are during mitosis, and we 
don’t know whether Golgi can reform 
de novo after mitosis, especially given 
the time frame.”
Meanwhile, resolution of the broader 
template versus no-template issue may 
come only if the temperature-sensitive 
Sar1 can be made and used to generate 
definitive results. For now, the only 
agreement is on a sentiment expressed 
by Nilsson. “This,” he says, “is not an 
issue that is in any way settled.”
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Figure 2. A Golgi enzyme and matrix 
protein colocalize to the ER in cells 
expressing an inactive Sar1 mutant.